Epirubicin, cisplatin, and capecitabine (ECX) is a combination of chemotherapy drugs used to treat metastatic and inoperable cancers of the stomach and the junction between the stomach and esophagus. However, many of these cancers return despite treatment. The purpose of this study is to see if adding the investigational drug rilotumumab to ECX chemotherapy is more effective than ECX alone when given as initial therapy in patients with metastatic or inoperable stomach and gastroesophageal cancers.
Rilotumumab works by blocking signals in the MET molecular pathway that drives cancer growth. It will only be given to patients whose cancer cells contain MET. Patients tumors’ also must not contain a protein called HER2; other treatments are available that target HER2.
Patients will be randomly assigned to receive ECX plus rilotumumab or ECX plus a placebo. Both treatments are given intravenously (by vein).